发明名称 Macrocyclic hepatitis C serine protease inhibitors
摘要 The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.
申请公布号 US8748374(B2) 申请公布日期 2014.06.10
申请号 US201113154721 申请日期 2011.06.07
申请人 AbbVie, Inc. 发明人 Chen Hui-Ju;McDaniel Keith F.;Green Brian E.;Shanley Jason P.;Kruger Albert W.;Gandarllla Jorge;Welch Dennie S.;Cink Russell D.;Cullen Steven C.;Gai Yonghua;Wang Guoqiang;Or Yat Sun
分类号 A61K38/00 主分类号 A61K38/00
代理机构 代理人
主权项 1. A compound of Formula I:wherein A is H, —(C═O)—O—R1, —(C═O)—R1, —(C═O)—N(R1R2), —S(O)2—R1, or —S(O)2—N(R1R2), each R1 is independently selected from the group consisting of: (i) H, aryl; substituted aryl; heteroaryl; substituted heteroaryl;(ii) heterocycloalkyl or substituted heterocycloalkyl; and(iii) —C1-C8 alkyl, —C2-C8 alkenyl or —C2-C8 alkynyl, each containing 0, 1, 2, or 3 heteroatoms independently selected from O, S, and N; substituted —C1-C8 alkyl, substituted —C2-C8 alkenyl or substituted —C2-C8 alkynyl, each containing 0, 1, 2, or 3 heteroatoms independently selected from O, S and N; —C3-C12 cycloalkyl, substituted —C3-C12 cycloalkyl; —C3-C12 cycloalkenyl, or substituted —C3-C12 cycloalkenyl; each R2 is independently selected from the group consisting of: (i) hydrogen;(ii) aryl; substituted aryl; heteroaryl; substituted heteroaryl;(iii) heterocycloalkyl or substituted heterocycloalkyl; and(iv) —C1-C8 alkyl, —C2-C8 alkenyl or —C2-C8 alkynyl, each containing 0, 1, 2, or 3 heteroatoms independently selected from O, S, and N; substituted —C1-C8 alkyl, substituted —C2-C8 alkenyl or substituted —C2-C8 alkynyl, each containing 0, 1, 2, or 3 heteroatoms independently selected from O, S and N; —C3-C12 cycloalkyl, substituted —C3-C12 cycloalkyl; —C3-C12 cycloalkenyl, or substituted —C3-C12 cycloalkenyl; G is —NHS(O)2—R3; each R3 is independently selected from: (i) C3-C12 cycloalkyl, substituted —C3-C12 cycloalkyl, aryl; substituted aryl; heteroaryl; substituted heteroaryl;(ii) heterocycloalkyl or substituted heterocycloalkyl; and(iii) —C1-C8 alkyl, —C2-C8 alkenyl or —C2-C8 alkynyl, each containing 0, 1, 2, or 3 heteroatoms independently selected from O, S, and N; substituted —C1-C8 alkyl, substituted —C2-C8 alkenyl or substituted —C2-C8 alkynyl, each containing 0, 1, 2, or 3 heteroatoms independently selected from O, S and N; —C3-C12 cycloalkenyl, or substituted —C3-C12 cycloalkenyl; and L is a C2-C5 saturated or unsaturated chain, optionally containing one to three heteroatoms independently selected from O, N and S(O)n, wherein L is optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano, C1-C6alkyl, C2-C6alkenyl and C2-C6alkynyl, wherein each C1-C6alkyl, C2-C6alkenyl and C2-C6alkynyl, group is optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl and cyano; Z is (i) —C1-C8 alkyl containing 0, 1, 2, or 3 heteroatoms independently selected from O, S, and N and optionally substituted with one or more halo; or (ii) thienyl or substituted thienyl; j=0, 1, 2, 3, or 4; k=0, 1, 2, or 3; m=0, 1, or 2; n is 0, 1, or 2; denotes a carbon-carbon single or double bond (i.e.,meansR6 is H or halo;R7 is H or halo;R8 is H or halo;R9 is H or halo; wherein if each of R6, R7, R8 and R9 is H, then Z is —C1-C8 alkyl substituted with one or more halo and containing 0, 1, 2, or 3 heteroatoms independently selected from O, S, and N; andsalts, solvates and hydrates thereof.
地址 North Chicago IL US